Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif.
| Revenue (Most Recent Fiscal Year) | $3.94M |
| Net Income (Most Recent Fiscal Year) | $-131.21M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 8.14 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -3317.62% |
| Net Margin (Trailing 12 Months) | -3326.01% |
| Return on Equity (Trailing 12 Months) | -190.19% |
| Return on Assets (Trailing 12 Months) | -71.29% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.86 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.86 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-7.50 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-3.41 |
| Earnings per Share (Most Recent Fiscal Year) | $-13.58 |
| Diluted Earnings per Share (Trailing 12 Months) | $-20.90 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 6.11M |
| Free Float | 5.58M |
| Market Capitalization | $32.10M |
| Average Volume (Last 20 Days) | 0.18M |
| Beta (Past 60 Months) | 2.72 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.75% |
| Percentage Held By Institutions (Latest 13F Reports) | 60.43% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |